Researchers from Pfizer Inc. report details of new studies and findings in the area of pharmacokinetics

Data detailed in "Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin" have been presented. According to a study from the United States, "A novel oral, extended-release, microsphere formulation of azithromycin (AZSR) was developed to improve the gastrointestinal tolerability profile while allowing administration of an entire treatment course of azithromycin in a single dose. Several phase I clinical pharmacology studies were conducted to (i) identify a well-tolerated single-dose formulation that met a predefined exposure target; and (ii) evaluate the effect of food and antacid on the absorption of this...

Want to see the full article?

• Purchase this article for only $3.00